Pohjolainen, Lotta http://orcid.org/0000-0001-8852-6709
Kinnunen, Sini M. http://orcid.org/0000-0003-1592-8306
Auno, Samuli http://orcid.org/0000-0003-2931-6853
Kiriazis, Alexandros
Pohjavaara, Saana http://orcid.org/0000-0003-4585-8652
Kari-Koskinen, Julia
Zore, Matej http://orcid.org/0000-0003-4230-1111
Jumppanen, Mikael
Yli-Kauhaluoma, Jari http://orcid.org/0000-0003-0370-7653
Talman, Virpi http://orcid.org/0000-0002-2702-6505
Ruskoaho, Heikki http://orcid.org/0000-0001-8971-1359
Välimäki, Mika J. http://orcid.org/0000-0002-9687-8197
Funding for this research was provided by:
Tekes (40395/13)
Academy of Finland (2666621, 321564, 328909)
Sydäntutkimussäätiö
Sigrid Juséliuksen Säätiö
University of Helsinki
Article History
Received: 12 May 2023
Accepted: 20 December 2023
First Online: 2 January 2024
Declarations
:
: Animal housing and termination were conducted according the 3R principles of the EU directive 2010/63/EU governing the care and use of experimental animals and following local laws and regulations (Finnish Act on the Protection of Animals Used for Scientific or Educational Purposes [497/2013], Government Decree on the Protection of Animals Used for Scientific or Educational Purposes [564/2013]). Primary cardiac cell cultures were prepared with an internal license of the project “Lead candidates for heart failure” approved by the University of Helsinki Laboratory Animal Centre (approval number KEK20-012, May 12th, 2020).
: Not applicable.
: SMK, MJV, MJ, JYK and HR are inventors in a patent application “Pharmaceutical compounds” (PCT/FI2017/050661). No other competing interests to disclose.